Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
PHASE1
Substudy 02B is part of a larger research study where researchers are looki...
Status
Completed
Location
The Angeles Clinic and Research Institute ( Site 2009)
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
PHASE1
Substudy 03B is part of a larger research study that is testing experimenta...
Status
Active Not Recruiting
Location
University of California at San Francisco ( Site 3008)
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
PHASE3
The goal of this study is to evaluate the efficacy and safety of pembrolizu...
Status
Active Not Recruiting
Location
The University of Alabama at Birmingham ( Site 0010)
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
PHASE1
Substudy 02D is part of a larger research study that is testing experimenta...
Status
Completed
Location
The Angeles Clinic and Research Institute ( Site 4009)
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
PHASE2
The purpose of this study is to evaluate the safety and efficacy of fixed d...
Status
Completed
Location
City of Hope Comprehensive Cancer Center ( Site 0002)
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
PHASE1
Substudy 02A is part of a larger research study that is testing experimenta...
Status
Completed
Location
The Angeles Clinic and Research Institute ( Site 1009)
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
PHASE3
The goal of this China extension study is to evaluate the efficacy and safe...
Status
Active Not Recruiting
Location
Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000)